Stockscreener 앱 받기
1.56
6.12%
0.09
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN
Leerink reiterates Akebia stock rating on regulatory precedent By Investing.com - Investing.com Australia
Akebia (AKBA) Initiates Phase 1 Trial for AKB-9090 Targeting Kid - GuruFocus
Akebia doses first patients in Phase 1 trial of AKB-9090 - Investing.com Canada
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 - The Manila Times
Akebia Therapeutics Leads The Pack Of 3 Promising Penny Stocks - Yahoo Finance
Akebia starts human testing of drug for kidney injury after heart surgery - Stock Titan
Profit Review: Is Akebia Therapeutics Inc attractive for institutional investorsGDP Growth & Momentum Based Trading Ideas - baoquankhu1.vn
Akebia Therapeutics (NASDAQ:AKBA) Rating Increased to Hold at Zacks Research - MarketBeat
Sectors Review: Is Akebia Therapeutics Inc stock trending bullishWeekly Risk Report & Detailed Earnings Play Strategies - baoquankhu1.vn
Block Trades: What is the next catalyst for Akebia Therapeutics IncQuarterly Profit Review & Consistent Growth Stock Picks - baoquankhu1.vn
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - marketscreener.com
BTIG Research Reaffirms "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat
Akebia executives head to New York for Apr. 14 biotech investor meetings - Stock Titan
BTIG Reiterates Buy Rating on AKBA with $4.00 Price Target | AKB - GuruFocus
H.C. Wainwright Keeps Their Buy Rating on Akebia Therapeutics (AKBA) - The Globe and Mail
Sell Signal: Does Akebia Therapeutics Inc offer margin of safetyMarket Trend Review & Smart Allocation Stock Tips - baoquankhu1.vn
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Fed Meeting: Is Akebia Therapeutics Incs ROIC above industry average2026 Trade Ideas & Safe Entry Zone Tips - baoquankhu1.vn
Akebia Therapeutics, Inc. (AKBA) stock price, news, quote and history - Yahoo Finance UK
H.C. Wainwright reiterates Akebia Therapeutics stock rating at buy By Investing.com - Investing.com Canada
How The Akebia Therapeutics (AKBA) Narrative Is Shifting After Vafseo Revenue And Protocol Updates - Yahoo Finance
Aug Sectors: What is the next catalyst for Akebia Therapeutics Inc2026 Fed Impact & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D DaySlideshow (NASDAQ:AKBA) 2026-04-04 - Seeking Alpha
Institutional Sell-Offs and Quiet Insiders Reveal Weak Confidence Behind Akebia's Pipeline Promotion - Bitget
Akebia (AKBA) director granted 214,400 options at $1.41, 3-year vest - Stock Titan
Akebia (NASDAQ: AKBA) director Philip J. Vickers files initial Form 3 - Stock Titan
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Akebia Therapeutics Issues Inducement Grants With Stock Options for New Employees - geneonline.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Akebia's Research and Development Day May Confirm or Undermine Its Kidney Treatment Strategy - Bitget
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
AKBA: Vafseo and a robust pipeline drive growth, with major clinical milestones expected by 2027 - TradingView — Track All Markets
AKBA: Innovative kidney disease pipeline advances with major clinical and commercial catalysts ahead - tradingview.com
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets - MarketBeat
Akebia Therapeutics adds Philip Vickers to board of directors By Investing.com - Investing.com South Africa
Akebia Therapeutics Appoints Philip Vickers, Ph.D. to Board of Directors – Company Details and Nasdaq Listing (2026) - Minichart
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors - Sahm
Akebia Therapeutics appoints biopharmaceutical leader Philip Vickers to its board of directors - marketscreener.com
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors - TradingView
Akebia Therapeutics (AKBA) appoints Philip Vickers to Board as Steven Gilman retires - Stock Titan
Akebia Therapeutics adds Philip Vickers to board of directors - Investing.com
AKBA.O PE Ratio & Valuation, Is AKBA.O Overvalued - Intellectia AI
AKBA Should I Buy - Intellectia AI
AKBA.O Technical Analysis & Stock Price Forecast - Intellectia AI
AKBA.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AKBA.O Forecast — Price Prediction for 2026. Should I Buy AKBA.O? - intellectia.ai
Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy - Insider Monkey
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - MSN
1.06%
1.05%
자본화:
|
볼륨(24시간):